Journal article · 2023 · Open access

Bioorthogonal PROTAC Prodrugs Enabled by On-Target Activation

Mengyang Chang, Feng Gao, Devin Pontigon, Giri Raj Gnawali, Hang Xu, Wei Wang

Journal of the American Chemical Society, 145(25), 14155–14163 · Published 16 June 2023 · DOI 10.1021/jacs.3c05159

Open PDFView at the publisherCite this paper

In brief

“Bioorthogonal PROTAC Prodrugs Enabled by On-Target Activation” is a 2023 journal article by Mengyang Chang and 5 co-authors, published in Journal of the American Chemical Society. OpenAlex counts 159 citations as of 19 November 2026, which puts it in the top 1% of works published in 2023 by citations. It is open access: the full text is free to read at PubMed Central.

Citations
159
Most cited in
2026 (58)
Field-weighted impact
11.21
References
72
Authors
6

Abstract

Although proteolysis targeting chimeras (PROTACs) have become promising therapeutic modalities, important concerns exist about the potential toxicity of the approach owing to uncontrolled degradation of proteins and undesirable ligase-mediated off-target effects. Precision manipulation of degradation activity of PROTACs could minimize potential toxicity and side effects. As a result, extensive efforts have been devoted to developing cancer biomarker activating prodrugs of PROTACs. In this investigation, we developed a bioorthogonal on-demand prodrug strategy (termed c lick- r elease “ cr PROTACs”) that enables on-target activation of PROTAC prodrugs and release of PROTACs in cancer cells selectively. Inactive PROTAC prodrugs TCO-ARV-771 and TCO-DT2216 are rationally designed by conjugating a bioorthogonal trans -cyclooctenes (TCO) group into the ligand of the VHL E3 ubiquitin ligase. The tetrazine (Tz)-modified RGD peptide, c (RGDyK)-Tz, which targets integrin α v β 3 biomarker in cancer cells, serves as the activation component for click-release of the PROTAC prodrugs to achieve targeted degradation of proteins of interest (POIs) in cancer cells versus noncancerous normal cells. The results of studies accessing the viability of this strategy show that the PROTAC prodrugs are selectively activated in an integrin α v β 3 -dependent manner to produce PROTACs, which degrade POIs in cancer cells. The cr PROTAC strategy might be a general, abiotic approach to induce selective cancer cell death through the ubiquitin-proteasome pathway.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Chang, M., Gao, F., Pontigon, D., Gnawali, G. R., Xu, H., & Wang, W. (2023). Bioorthogonal PROTAC Prodrugs Enabled by On-Target Activation. Journal of the American Chemical Society, 145(25), 14155–14163. https://doi.org/10.1021/jacs.3c05159

MLA 9

Chang, Mengyang, et al. “Bioorthogonal PROTAC Prodrugs Enabled by On-Target Activation.” Journal of the American Chemical Society, vol. 145, no. 25, 2023, pp. 14155–14163. https://doi.org/10.1021/jacs.3c05159.

Chicago

Chang, Mengyang, Feng Gao, Devin Pontigon, Giri Raj Gnawali, Hang Xu, and Wei Wang. 2023. “Bioorthogonal PROTAC Prodrugs Enabled by On-Target Activation.” Journal of the American Chemical Society 145 (25): 14155–14163. https://doi.org/10.1021/jacs.3c05159.

Harvard

Chang, M. et al. (2023) ‘Bioorthogonal PROTAC Prodrugs Enabled by On-Target Activation’, Journal of the American Chemical Society, 145(25), pp. 14155–14163. doi:10.1021/jacs.3c05159.

IEEE

M. Chang, F. Gao, D. Pontigon, G. R. Gnawali, H. Xu, and W. Wang, “Bioorthogonal PROTAC Prodrugs Enabled by On-Target Activation,” Journal of the American Chemical Society, vol. 145, no. 25, pp. 14155–14163, 2023, doi: 10.1021/jacs.3c05159.

BibTeX

@article{chang2023bioorthogonal,
  title     = {{Bioorthogonal PROTAC Prodrugs Enabled by On-Target Activation}},
  author    = {Chang, Mengyang and Gao, Feng and Pontigon, Devin and Gnawali, Giri Raj and Xu, Hang and Wang, Wei},
  journal   = {Journal of the American Chemical Society},
  year      = {2023},
  volume    = {145},
  number    = {25},
  pages     = {14155--14163},
  doi       = {10.1021/jacs.3c05159},
  url       = {https://doi.org/10.1021/jacs.3c05159}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Citations by year

YearCitationsShare of the best year
20231212
20243737
20255252
20265858

Its field-weighted citation impact is 11.21: it has been cited 11.21 times as often as the average work of the same field, type and year (1.00 is the world average).

Topic and keywords

Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors

  • PROTACs
  • trans-cyclooctene
  • VHL E3 ubiquitin ligase
  • tetrazine
  • RGD peptide
  • integrin αvβ3
  • targeted protein degradation
  • ubiquitin-proteasome system

Work with this paper

Most-cited papers in Biochemistry, Genetics and Molecular Biology

All highly cited Biochemistry, Genetics and Molecular Biology papers

Questions about this paper

How do I cite this paper in APA style?

Chang, M., Gao, F., Pontigon, D., Gnawali, G. R., Xu, H., & Wang, W. (2023). Bioorthogonal PROTAC Prodrugs Enabled by On-Target Activation. Journal of the American Chemical Society, 145(25), 14155–14163. https://doi.org/10.1021/jacs.3c05159

How many times has this paper been cited?

159 times, according to OpenAlex on 19 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at PubMed Central: sign in and open the PDF from this page.

Who wrote this paper?

Mengyang Chang, Feng Gao, Devin Pontigon, Giri Raj Gnawali, Hang Xu, Wei Wang.

What is the DOI of this paper?

10.1021/jacs.3c05159, permanently at https://doi.org/10.1021/jacs.3c05159. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 19 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.